Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions
Huntington DiseaseIrritability
Interventions
DRUG

Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)

DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.

DRUG

Placebo

Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
collaborator

Cures Within Reach

OTHER

lead

The University of Texas Health Science Center, Houston

OTHER

NCT03854019 - Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease | Biotech Hunter | Biotech Hunter